Introduction
============

Esophageal cancer (EC) is one of the most lethal types of malignancy, leading to the death of 400.000 people worldwide in 2012.[@b1-cmar-10-1585] It could be primarily divided into squamous cell carcinoma and adenocarcinoma. Esophageal squamous cell carcinoma (ESCC) is the primary histological type of EC in most EC high-incidence areas, including the People's Republic of China, Middle East, and southern Africa. The molecular mechanism of EC tumorigenesis remains unclear, and the primary risk factors for ESCC are smoking and alcohol consumption.[@b2-cmar-10-1585] Most EC patients are diagnosed at advanced stages because of its silent onset and aggressive nature. Current treatments for EC patients are surgery and chemoradiotherapy. Different from other types of cancer, in which molecular markers have been extensively studied and applied in clinics to assist diagnosis and prognosis prediction, very few advances have been made in ESCC. A strong need for the discovery of new biomarkers in ESCC is emerging.

INHBA is a gene located at 7p14.1, encoding a member of the TGF-beta superfamily of proteins.[@b3-cmar-10-1585] The ligand could be further homo-dimerized to form activin A or hetero-dimerized to form inhibin with inhibin beta B. The involvement of activin A has been observed in multiple biological activities, such as stem cell differentiation,[@b4-cmar-10-1585] glucose metabolism,[@b5-cmar-10-1585] immune response,[@b6-cmar-10-1585] and tumor development.[@b7-cmar-10-1585] Recently, the overexpression of INHBA has been reported in multiple types of cancers, including breast cancer,[@b7-cmar-10-1585] colorectal cancer,[@b8-cmar-10-1585] gastric cancer,[@b9-cmar-10-1585] lung cancer,[@b10-cmar-10-1585] and bladder cancer.[@b11-cmar-10-1585] However, the prognostic effects of INHBA in ESCC remain unclear.

In this study, we collected 239 ESCC patient samples and measured the expression of INHBA with IHC to study the clinical significance of INHBA expression in ESCC. To further explore the prognostic meaning of INHBA expression, we gathered six already published manuscripts and conducted a meta-analysis of INHBA expression in multiple types of solid tumors. The aim of this study is to have a better understanding of the clinical significance of INHBA expression.

Material and methods
====================

Meta-analysis -- literature search
----------------------------------

A search was performed for eligible literature in PubMed and Web of Science from 2000 to November 2017. All literature had to be published in English. The keywords used in the search included "INHBA", "Inhibin beta A", "cancer", and "prognosis". The last date of search was November 18, 2017. We retrieved eligible manuscripts for data extraction and analysis.

Meta-analysis -- selection criteria
-----------------------------------

Literature was collected according to the following criteria: 1) published in English; 2) primary cancer which had been previously histopathologically diagnosed; 3) level of INHBA had been detected before surgery; 4) HRs and their 95% CIs were calculated in all studies; and 5) only the most recent data were included if the same group published multiple studies.

Meta-analysis -- data extraction and quality assessment
-------------------------------------------------------

Two independent researchers (Lyu and Jiang) assessed the quality of the selected studies, using Revman5.3, as recommended by Cochrane Collaboration. Different factors were extracted for quality assessments, including clear description of purpose/objectives, clear description of patients' eligibility criteria (including/excluding), clear description of INHBA detection, predefinition of predictors (disease-free survival \[DFS\]/cancer-specific survival/overall survival \[OS\]) and outcome measurements, long enough follow-up period, and limitations considered, modified from Perisanidis et al.[@b12-cmar-10-1585] We ranked the included papers according to the quality items used in each study (score range 0--6, [Table S1](#SD2-cmar-10-1585){ref-type="supplementary-material"}). Quality assessment was not used as exclusion criterion for the eligible studies. We (Lyu and Xu) extracted data from each study for analysis, including author, country, year of publication, study type and study period, cancer type and stage of cancers, number of patients and male patient ratio, and INHBA HR with its 95% CI. Disagreements were resolved by discussion. Publication bias was assessed by Begg's funnel plot in Revman5.3 and Egger's test in R programming language. "Trim and fill" method was used to adjust HRs if publication bias was found.

Tissue and patient sources
--------------------------

The study was approved by the medical ethics committee of Sun Yat-sen University Cancer Center. In total, 239 specimens from ESCC patients who underwent surgery in the hospital were sectioned and confirmed by pathological review of IHC. All the ESCC patients were seen from 2000 to 2007 at the hospital and were clinically and histologically diagnosed. All patients were treated with radical surgery without neoadjuvant/adjuvant treatments. We used the 7th edition of the TNM classification of the International Union Against Cancer (2009) to record the histologic grade and the clinical stage of the tumors. The selection criteria are as follows: 1) histologically confirmed primary ESCC without any previous treatment; 2) no familial malignancies or other synchronous malignancies history; 3) underwent resection plus lymphadenectomy (limited or extended); and 4) clinical information and follow-up data were documented. Clinical data were obtained from the hospital records, and all the patients were contacted in 2012 to determine their vital status. Patients whose tissues and medical records were used for this study had provided written informed consent.

Tissue microarray construction
------------------------------

The tissue microarray was constructed according to methods that were described previously.[@b13-cmar-10-1585] Tissues from all the patients in this study were collected, fixed in ethanol, and embedded in paraffin. A senior pathologist reviewed and defined representative tumor regions through hematoxylin and eosin staining. Two targeted core samples of each specimen were obtained using a tissue array instrument (MiniCore instruments; Alphelys, Plaisir, France). Tissue cylinders with a diameter of 10 mm were punched and arrayed on a recipient paraffin block. Sections of the tissue array were cut and placed onto glass slides.

Immunohistochemical staining and assessment
-------------------------------------------

The tissue slides were rehydrated by a graded alcohol series. Then the slides were incubated in 0.3% hydrogen peroxide for 15 minutes to quench the endogenous peroxidase activity. Tris (hydroxymethyl) aminomethane-EDTA buffer (pH 8.0) was used in antigen retrieval. We used 10% normal goat serum for 10 minutes to block nonspecific binding. The slides were incubated with polyclonal antibody against INHBA (1:1000, ab56057, Abcam, USA) for 12 hours at 4°C in a moist chamber. We used blocking solutions without primary antibody as a control. The slides were then incubated with horseradish peroxidase for 30 minutes and 3,30-diaminobenzidine solution for visualization. Mayer's hematoxylin was applied as a counterstain. Internal positive and negative controls, including normal squamous mucosa of the esophagus from cancer-free patients, were also used to further support the staining patterns. Two independent pathologists (Lyu and Jiang), who were blinded to the clinicopathologic data, generated the immunoreactivity score (IRS) for INHBA expression. They scored the results based on the following criteria: 1) percentage of positive tumor cells in the tumor tissue: zero (0%), 1 (1%--10%), 2 (11%--50%), 3 (51%--70%), and 4 (71%--100%); and 2) signal intensity: zero (no signal), 1 (weak), 2 (median), and 3 (strong). The IRS was calculated by multiplying the score for the percentage of positive cells by the intensity score (range, 0--12). The specimens were rescored if the difference between the scores by the two pathologists was \>3.

Statistical analysis
--------------------

We performed the meta analysis with Revman5.3 (The Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen, Denmark). The details have been previously described.[@b14-cmar-10-1585] Statistical heterogeneity between studies was determined by Cochran's Q test and Higgins I^2^. Sensitivity analysis was performed by omitting each study or specific studies to find potential outliers in R, using "metainf " and "forest" function in "meta" package. *P*\<0.1 or I^2^\>50% was considered as heterogeneity. A random effects model was used to combine data if statistically significant heterogeneity was found. We did not do subgroup analysis as the research papers are few. Publication bias was assessed by funnel plot as well as Begg's and Egger's test in R software.

Survival analysis was performed with SPSS software (standard version 16.0, SPSS Inc., Chicago, IL, USA). The ROC method was used to define the cutoff value for the INHBA IRS. The ROC curve was generated by the MedCalc statistical software package 11.0.1 (MedCalc Software bvba, Mariakerke, Belgium). Pearson's χ^2^ test was used to define the correlation between INHBA expression and clinicopathological features of the patients. A binary logistic regression model was used to analyze the variables that correlated with INHBA expression. DFS survival was defined as the time from surgery to regional relapse or the development of distant metastasis. OS was defined as the time from surgery to death. DFS and OS were assessed with the Kaplan--Meier method and were compared by the log-rank test. A multivariate survival analysis was performed for all of the variables that were significant in the univariate analysis using the Cox regression model. For all analyses, a two-sided *P*-value \<0.05 was considered statistically significant.

Results
=======

Literature search
-----------------

After the initial literature search, 15 were included for further analysis after reviewing the abstracts. Eight full text articles were retrieved for data extraction. Finally, six studies were included in this meta-analysis. The flow chart in [Figure 1](#f1-cmar-10-1585){ref-type="fig"} shows the process of identifying studies. A total of 1321 patients were included and the characteristics of the studies were summarized in [Table 1](#t1-cmar-10-1585){ref-type="table"}.[@b8-cmar-10-1585],[@b9-cmar-10-1585],[@b11-cmar-10-1585],[@b15-cmar-10-1585]--[@b17-cmar-10-1585]

Meta-analysis results
---------------------

The average quality assessment was fair (4.2/6.0), with a median score of 4 ([Table S1](#SD2-cmar-10-1585){ref-type="supplementary-material"}). To evaluate the prognostic effect of INHBA in ESCC, we used the multivariate HRs and their 95% CIs in these studies to calculate a combined HR. The estimated proportion of heterogeneity (I[@b2-cmar-10-1585]) between six INHBA studies was 49% (*P*=0.07) for the survival rates. Therefore, significant heterogeneity existed, and a random model was applied. We did the sensitivity analysis ([Figure S1A](#SD1-cmar-10-1585){ref-type="supplementary-material"}) and we established that Okano et al's[@b8-cmar-10-1585] study was very sensitive in this analysis. All other studies had an HR \>2 and 95% CI \>1. However, Okano et al's study had an HR 1.16 and 95% CI from 0.71--1.88. Apart from this study, all other studies were very consistent.

Patients with a higher INHBA level had lower survival rates than patients with a lower INHBA level. High INHBA was a rick factor for poor prognosis (HR 2.50, 95% CI 1.75--3.57, *P*\<0.0001, [Figure 2A](#f2-cmar-10-1585){ref-type="fig"}). Begg's funnel test was performed to estimate the existing publication bias of the literature in this meta-analysis. As shown in [Figure 2B](#f2-cmar-10-1585){ref-type="fig"}, the shape of the Funnel plots showed some evidence of asymmetry, which was confirmed by Egger's regression test (*P*=0.0010) and Begg's test, (*P*=0.0004). Small studies normally show larger effect sizes. Some small studies with insignificant findings are harder to publish, and therefore they were not included in our meta-analysis. After we used the "trim and fill" method to adjust for publication bias under the random effects model, the corrected pooled HR for survival was 2.1409 (95% CI =1.5271--3.0014, *P*\<0.0001, [Figure S1B](#SD1-cmar-10-1585){ref-type="supplementary-material"}).

Expression of INHBA in ESCC tissue
----------------------------------

The INHBA protein expression in ESCC was examined by IHC in 239 ESCC patients. The average age of the patients was 57.53 years old (range, 32--80). The clinicopathological characteristics of the population were listed in [Table 2](#t2-cmar-10-1585){ref-type="table"} and the representative figures of INHBA expression in ESCC and the adjacent normal mucosal tissues were listed in [Figure 3](#f3-cmar-10-1585){ref-type="fig"}. INHBA expression in the adjacent normal tissues was nonexistent ([Figure 3A](#f3-cmar-10-1585){ref-type="fig"}) while weak, median, and strong INHBA expression was observed predominantly in the cytoplasm of cells in the ESCC tissues ([Figure 3C-H](#f3-cmar-10-1585){ref-type="fig"}).

Selection of the cutoff value
-----------------------------

We used ROC curve to define the cutoff value for the INHBA IRS. The point with both maximum sensitivity and specificity was selected as the cutoff value. In this study, the IRS cutoff value was 8. The sensitivity was 0.800 and specificity was 0.632. The area under the ROC curve was 0.593. Thus, high expression of CEP55 was defined when the IRS was ≥8 (*P*\<0.05); otherwise, the expression was defined as low.

INHBA expression and clinicopathological variables
--------------------------------------------------

The relationships between clinicopathological features of patients with ESCC and INHBA expression were summarized in [Table 2](#t2-cmar-10-1585){ref-type="table"}. The INHBA expression closely correlated with N categories (*P*=0.026). No statistical correlations were found between INHBA expression and age, sex, tumor location, histological grade, T status, and TNM stage (*P*\>0.05).

INHBA expression and patients' survival
---------------------------------------

No patients were lost to follow-up among the 239 patients. The median observation period was 40 months (range 4--115 months). A total of 125 patients were deceased at the end of the follow-up period while 114 were alive. The 5-year DFS and OS of the entire cohort were 31% and 36%, with median survival times of 38 months and 40 months for patients with high and low expression.

According to the Kaplan--Meier analysis, INHBA expression in ESCC was closely related to DFS and OS. The median DFS was 58 months for patients with low INHBA expression, whereas it was 31 months for patients with high INHBA expression (*P*=0.001; [Figure 4A](#f4-cmar-10-1585){ref-type="fig"}). The median OS was 58 months for patients with low INHBA expression, whereas it was 37 months for patients with high INHBA expression (*P*=0.001; [Figure 4B](#f4-cmar-10-1585){ref-type="fig"}). In the INHBA subgroup analysis, INHBA distinguished DFS and OS when patients were stratified by TNM stage status and N status. For stage 1 and stage 2 patients, the average DFS and OS were 94 and 95 months for patients with low INHBA expression, whereas it was 68 and 71 months for patients with high INHBA expression (*P*=0.009 and *P*=0.008, [Figure 4C, D](#f4-cmar-10-1585){ref-type="fig"}). For N0 patients, the average DFS and OS were 94 and 95 months, respectively, for patients with low INHBA expression, whereas they were 71 and 73 months, respectively, for patients with high INHBA expression (*P*=0.022 and *P*=0.023, [Figure 4E, F](#f4-cmar-10-1585){ref-type="fig"}).

A univariate analysis using the Cox proportional hazards model was applied to assess the importance of multiple factors in the survival times of ESCC patients. The result showed that the following parameters correlated significantly with DFS and OS: T category, N category, TNM stage, and INHBA expression ([Table 3, *P*](#t3-cmar-10-1585){ref-type="table"}\<0.001, *P*\<0.001, *P*\<0.01, and *P*=0.001, respectively). When the aforementioned parameters were included in a multivariate analysis, the results suggested that T category, N category, and INHBA expression were independent factors that affected OS and PFS ([Table 4](#t4-cmar-10-1585){ref-type="table"}).

Discussion
==========

In this study, we studied the relations of relative expression of the INHBA gene to clinicopathological factors and outcomes in patients with ESCC after surgery. In addition, we conducted a meta-analysis to further elucidate the prognostic role of INHBA in solid tumors.

Previous studies have shown that the expression of INHBA is associated with prognosis of different types of cancer patients. Okano et al[@b8-cmar-10-1585] reported that high expression of INHBA gene was associated with significantly poorer 5-year OS in colorectal cancer. Oshima et al[@b15-cmar-10-1585] found that gastric cancer patients with high INHBA expression showed significantly worse OS when compared to those with low INHBA expression. Two other independent groups reported similar results, showing that INHBA expression could be a useful tool to predict outcomes in gastric cancer.[@b9-cmar-10-1585],[@b16-cmar-10-1585] Consistently, we found that INHBA expression is higher in ESCC samples when compared with corresponding normal tissues and correlated with lymph node metastasis. One earlier study mentioned elevated levels of INHBA in ESCC patients, but we are the first to identify IHNBA as an independent prognostic factor in ESCC patients.[@b18-cmar-10-1585] What is more, the meta-analysis comprised nine studies of INHBA expression in six different types of cancer, showing that INHBA expression is a promising predictor of patient survival in solid tumors. Our results confirmed and extended the fact that high INHBA expression predicts poor prognosis in solid tumors to ESCC.

However, the molecular mechanism and tumor promoting functions of INHBA remain elusive. Most of the hypotheses are focused on tumor metastasis. Wamsley et al reported that activin is required to sustain cancer stem-like cells phenotypes and contributes to metastasis in non-small cell lung cancer.[@b19-cmar-10-1585] Chang et al also found that activin A promotes tumor invasion and metastasis in head and neck squamous cell carcinoma.[@b20-cmar-10-1585] Yoshinaga et al reported that INHBA promoted tumor aggressiveness by associating with N-cadherin.[@b21-cmar-10-1585] Our findings confirmed that INHBA level correlated with lymph node metastasis in ESCC and might contribute to a worse prognosis. On the other hand, Seder et al found that INHBA was overexpressed in esophageal adenocarcinoma and promoted cell proliferation by promoter demethylation and histone acetylation.[@b22-cmar-10-1585] Our own study and meta-analysis supported the oncogenic effects of INHBA in cancers. On the contrary, roles played by INHBA vary in different contexts of cancer. Panopoulou et al found that activin A suppresses neuroblastoma xenograft tumor growth via ALK4/SMAD2-SMAD3 pathways.[@b23-cmar-10-1585] Kaneda et al demonstrated that activin A inhibits vascular endothelial cell growth and suppresses tumor angiogenesis in gastric cancer.[@b24-cmar-10-1585] The molecular mechanism and pleiotropic functions of INHBA in cancers warrant further studies.

This study shed light on the clinical role of INHBA in ESCC, providing new evidence of its oncogenic functions. However, it also has several limitations. We only included ESCC samples in the study since it was the primary subtype in our patients. All patients were recruited from one single institute. Further multicenter studies are needed to verify our observations. In addition, the number of papers included in the meta-analysis is relatively low. Finally, IHC method is useful to evaluate clinical significance of INHBA, but it failed to answer mechanistic questions.

Conclusion
==========

Our study showed that INHBA gene expression levels were higher in cancer tissue of patients with ESCC than in normal mucosa. High expression of this gene was significantly related to lymph node metastasis and poor prognosis. Combined with the meta-analysis, our findings suggest that the overexpression of INHBA is a useful predictor of prognosis in patients with ESCC.

Supplementary materials
=======================

###### 

Sensitivity analysis.

**Notes:** Sensitivity test of the meta-analysis (**A**). "Trim and fill" method to adjust for publication bias in this meta study (**B**).

###### 

Quality assessment of the selected papers

  Study                               Year   Country                      Clear description of purpose/objectives   Clear description of patient selection criteria   Clear description of INHBA detection   Predefinition of predictors and outcome measurements   Whether or not multivariate analysis and/or univariate analysis was used   Long enough follow-up period   Limitations considered   Quality (0--6)
  ----------------------------------- ------ ---------------------------- ----------------------------------------- ------------------------------------------------- -------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------------- ------------------------------ ------------------------ ----------------
  Lee et al[@b28-cmar-10-1585]        2014   Taiwan                       Yes                                       No                                                Yes                                    No                                                     Yes                                                                        Yes                            Yes                      5
  Wang et al[@b31-cmar-10-1585]       2016   People's Republic of China   Yes                                       No                                                Yes                                    No                                                     Yes                                                                        Yes                            No                       4
  Okano et al[@b26-cmar-10-1585]      2013   Japan                        Yes                                       No                                                Yes                                    No                                                     Yes                                                                        Yes                            No                       4
  Oshima et al[@b29-cmar-10-1585]     2014   Japan                        Yes                                       No                                                Yes                                    No                                                     Yes                                                                        Yes                            No                       4
  Wang et al[@b27-cmar-10-1585]       2012   People's Republic of China   Yes                                       No                                                Yes                                    No                                                     Yes                                                                        Yes                            No                       4
  Katayama et al[@b30-cmar-10-1585]   2017   Japan                        Yes                                       No                                                Yes                                    No                                                     Yes                                                                        Yes                            No                       4
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![Flow chart of meta-analysis literature search.](cmar-10-1585Fig1){#f1-cmar-10-1585}

![Meta-analysis plots.\
**Notes:** Forest plot of HR for the association of high plasma INHBA level and survival (**A**). Begg's funnel plots of publication bias (**B**).\
**Abbreviation:** UTC, upper tract urothelial carcinoma.](cmar-10-1585Fig2){#f2-cmar-10-1585}

![INHBA expression determined by IHC.\
**Notes:** Normal esophageal tissue demonstrated no expression of INHBA protein in the cytoplasm of esophageal squamous cells (magnification: **A**, ×40; **B**, ×200). Low expression level of INHBA in ESCC tissues (magnification: **C**, ×40; **D**, ×200). Median expression of INHBA in ESCC tissues (magnification: **E**, ×40; **F**, ×200). High expression levels of INHBA were detected in ESCC tissues (magnification: **G**, ×40; **H**, ×200).\
**Abbreviations:** ESCC, esophageal squamous cell carcinoma; IHC, immunohistochemistry.](cmar-10-1585Fig3){#f3-cmar-10-1585}

![Disease-free survival (DFS) and overall survival (OS) curves according to patients' INHBA expression.\
**Notes:** DFS curve in all patients with different levels of INHBA expression (**A**, *P*=0.001). OS curve in all patients with different levels of INHBA expression (**B**, *P*=0.001). DFS and OS curves in patients in TNM stage 1 and 2 with low and high INHBA expression (**C**, **D**, *P*=0.009 and *P*=0.008, respectively). DFS and OS curves in patients in N0 stage with low and high INHBA expression (**E**, **F**, *P*=0.022 and *P*=0.023, respectively).](cmar-10-1585Fig4){#f4-cmar-10-1585}

###### 

The characteristics of the included studies

  Study                               Year   Country                      Study type (R or P)   Study Period   Cancer site                            Stage   N     Sex (male)   U/M   HRs     Outcome 1   In (HR)   SE
  ----------------------------------- ------ ---------------------------- --------------------- -------------- -------------------------------------- ------- ----- ------------ ----- ------- ----------- --------- -------
  Lee et al[@b11-cmar-10-1585]        2014   Taiwan                       R                     1996--2004     Urinary bladder urothelial carcinoma   1--4    340   0.465        U     2.825   DSS         1.039     0.328
  Lee et al[@b11-cmar-10-1585]        2014   Taiwan                       R                     1996--2004     Upper urinary tract carcinoma          1--4    295   0.732        U     2.803   DSS         1.031     0.368
  Wang et al[@b16-cmar-10-1585]       2016   People's Republic of China   R                     2001--2012     Breast cancer                          1--3    126                U     3.311   OS          1.197     0.386
  Okano et al[@b8-cmar-10-1585]       2013   Japan                        R                     1990--2002     Colorectal cancer                      1--4    126   0.595        M     1.160   OS          0.148     0.247
  Oshima et al[@b14-cmar-10-1585]     2014   Japan                        R                     2002--2007     Gastric cancer                         1--3    168   0.673        U     3.048   OS          1.114     0.396
  Wang et al[@b9-cmar-10-1585]        2012   People's Republic of China   R                     2004--2006     Gastric cancer                                 132   0.621        U     2.380   OS          0.867     0.349
  Katayama et al[@b15-cmar-10-1585]   2017   Japan                        R                     2002--2010     Gastric cancer                         2--3    134   0.687        U     3.926   OS          1.368     0.379

**Abbreviations:** OS, overall survival; DSS, disease-specific survival; R, research; P, prospective cohort study; U, univariate analysis; M, multivariate analysis; HR, hazard ration.

###### 

INHBA expression and other important clinicopathological parameters in esophageal squamous cell carcinoma

  Variables                                                        Cases (n=239)   INHBA expression   *P*-value[a](#tfn2-cmar-10-1585){ref-type="table-fn"}   
  ---------------------------------------------------------------- --------------- ------------------ ------------------------------------------------------- -----------
  Age, years[b](#tfn3-cmar-10-1585){ref-type="table-fn"}                                                                                                      0.504
   ≤58                                                             127             39 (30.7)          88 (69.3)                                               
   \>58                                                            112             30 (26.8)          82 (73.2)                                               
  Sex                                                                                                                                                         0.634
   Female                                                          64              17 (26.6)          47 (73.4)                                               
   Male                                                            175             52 (28.0)          123 (72.0)                                              
  Tumor location                                                                                                                                              0.171
   Upper                                                           12              4 (33.3)           8 (66.7)                                                
   Middle                                                          163             41 (25.2)          122 (74.8)                                              
   Lower                                                           64              24 (37.5)          40 (62.5)                                               
  Histological grade[c](#tfn4-cmar-10-1585){ref-type="table-fn"}                                                                                              0.1
   Grade 1                                                         58              23 (39.7)          37 (60.3)                                               
   Grade 2                                                         154             38 (24.7)          116 (75.3)                                              
   Grade 3                                                         27              8 (29.6)           19 (70.4)                                               
  pT status[c](#tfn4-cmar-10-1585){ref-type="table-fn"}                                                                                                       0.458
   pT 1                                                            6               3 (50.0)           3 (50.0)                                                
   pT 2                                                            55              15 (27.3)          40 (72.7)                                               
   pT 3                                                            175             51 (29.1)          124 (70.9)                                              
   pT 4                                                            3               0 (0.00)           2 (100.0)                                               
  N categories                                                                                                                                                **0.026**
   Negative                                                        129             45 (34.9)          84 (65.1)                                               
   Positive                                                        110             24 (21.8)          86 (78.2)                                               
  TNM stage                                                                                                                                                   0.172
   Stage 1                                                         9               3 (33.3)           6 (66.7)                                                
   Stage 2                                                         138             46 (33.3)          92 (66.7)                                               
   Stage 3                                                         91              20 (22.0)          71 (78.0)                                               

**Notes:**

Probability value of \<0.05 indicates statistical significance shown in bold. Probability values were calculated by Pearson's χ^2^ test.

Age was divided according to the median age of 58 years.

The grading and histopathology staging of ESCC specimens was based on the World Health Organization classification published in 2009.[@b25-cmar-10-1585]

**Abbreviation:** ESCC, esophageal squamous cell carcinoma.

###### 

Univariate Cox regression analysis in ESCC patients for disease-free survival and overall survival

  Variables                                                        Disease-free survival     Overall survival                             
  ---------------------------------------------------------------- ------------------------- ------------------ ------------------------- ---------
  Age, years[a](#tfn6-cmar-10-1585){ref-type="table-fn"}                                     0.704                                        0.691
   ≤58                                                             Reference                                    Reference                 
   \>58                                                            0.935 (0.658--1.328)                         0.932 (0.656--1.324)      
  Sex                                                                                        0.293                                        0.218
   Male                                                            Reference                                    Reference                 
   Female                                                          1.241 (0.827--1.863)                         1.288 (0.858--1.933)      
  Tumor location                                                                             0.323                                        0.288
   Upper                                                           1.586 (0.758--3.317)                         1.551 (0.742--3.243)      
   Middle                                                          0.945 (0.631--1.415)                         0.905 (0.604--1.356)      
   Lower                                                           Reference                                    Reference                 
  Histological grade[b](#tfn7-cmar-10-1585){ref-type="table-fn"}                             0.131                                        0.181
   Grade 1                                                         Reference                                    Reference                 
   Grade 2                                                         1.028 (0.674--1.568)                         1.016 (0.666--1.550)      
   Grade 2                                                         1.688 (0.940--3.031)                         1.609 (0.896--2.891)      
  pT status[b](#tfn7-cmar-10-1585){ref-type="table-fn"}                                      \<0.001                                      \<0.001
   pT 1                                                            Reference                                    Reference                 
   pT 2                                                            1.496 (0.354--6.318)                         1.660 (0.393--7.013)      
   pT 3                                                            1.960 (0.483--7.958)                         2.251 (0.554--9.146)      
   pT 4                                                            35.323 (5.438--229.431)                      63.931 (9.762--418.677)   
  pT1-2                                                                                      0.005                                        0.005
   Low expression                                                  Reference                                    Reference                 
   High expression                                                 4.709 (1.413--15.690)                        4.745 (1.425--15.804)     
  pT3-4                                                                                      0.034                                        0.030
   Low expression                                                  Reference                                    Reference                 
   High expression                                                 1.657 (1.030--2.666)                         1.673 (1.040--2.692)      
  pN status[b](#tfn7-cmar-10-1585){ref-type="table-fn"}                                      \<0.001                                      \<0.001
   0                                                               Reference                                    Reference                 
   1--3                                                            3.257 (2.243--4.730)                         3.410 (2.347--4.954)      
  pN0                                                                                        0.022                                        0.023
   Low expression                                                  Reference                                    Reference                 
   High expression                                                 2.216 (1.097--4.479)                         2.200 (1.089--4.445)      
  pN1-3                                                                                      0.230                                        0.134
   Low expression                                                  Reference                                    Reference                 
   High expression                                                 1.403 (0.798--2.466)                         1.527 (0.867--2.689)      
  pStage[b](#tfn7-cmar-10-1585){ref-type="table-fn"}                                         \<0.001                                      \<0.001
   Stage 1                                                         Reference                                    Reference                 
   Stage 2                                                         1.095 (0.342--3.509)                         1.073 (0.335--3.440)      
   Stage 3                                                         3.852 (1.209--12.275)                        4.070 (1.276--12.986)     
  pStage 1/2                                                                                 0.009                                        0.008
   Low expression                                                  Reference                                    Reference                 
   High expression                                                 2.352 (1.212--4.565)                         2.365 (1.219--4.590)      
  pStage 3                                                                                   0.277                                        0.223
   Low expression                                                  Reference                                    Reference                 
   High expression                                                 1.379 (0.763--2.492)                         1.436 (0.792--2.603)      
  CEP55 expression                                                                           0.001                                        0.001
   Low                                                             Reference                                    Reference                 
   High                                                            2.023 (1.304--3.139)                         2.053 (1.323--3.185)      

**Notes:**

Age is divided according to the median age of the study.

The grading and histopathology stage of ESCC specimens are based on the World Health Organization classification published in 2009.[@b25-cmar-10-1585]

**Abbreviation:** ESCC, esophageal squamous cell carcinoma.

###### 

Multivariate Cox regression analysis for disease-free survival and overall survival in patients with esophageal squamous cell carcinoma

  Variables                                               Disease-free survival    Overall survival                              
  ------------------------------------------------------- ------------------------ ------------------ -------------------------- ---------
  pT status[a](#tfn9-cmar-10-1585){ref-type="table-fn"}                            \<0.001                                       \<0.001
   pT 1                                                   1.000                                       1.000                      
   pT 2                                                   1.395 (0.330--5.903)                        1.665 (0.393--7.057)       
   pT 3                                                   1.734 (0.426--7.058)                        2.137 (0.524--8.718)       
   pT 4                                                   32845 (5.021--214.879)                      69.057 (10.246--465.429)   
  pN categories                                                                    \<0.001                                       \<0.001
   N0                                                     1.000                                       1.000                      
   N1--3                                                  3.094 (2.123--4.510)                        3.294 (2.258--4.804)       
  CEP55 expression                                                                 0.022                                         0.017
   Low                                                    1.000                                       1.000                      
   High                                                   1.679 (1.077--2.619)                        1.715 (1.100--2.675)       

**Note:**

The grading and histopathology stage of ESCC specimens are based on the World Health Organization classification published in 2009.[@b25-cmar-10-1585]

**Abbreviation:** ESCC, esophageal squamous cell carcinoma.
